ALFASIGMA AT ECCO CONGRESS 2025
Alfasigma is excited to announce that new findings from the multicenter-multicountry GALOCEAN (ph4) and SELECTION (ph3) studies, focusing on patients with moderate to severe Ulcerative Colitis, will b...
Read more
Alfasigma acquires the European license for bentracimab from PhaseBio
The agreement covers the countries of the European Union, the European Economic Area, the United Kingdom, Ukraine, Russia and the CIS. Bentracimab is a human monoclonal antibody fragment to counterac...
Read more
Online About Carnitine: the new portal for healthcare professionals
About Carnitine is the leading online global destination for healthcare professionals worldwide, offering the latest medical insights, expert perspectives and relevant professional education about t...
Read more
Alfasigma: It's Vein Week from 5th to 11th of April
v-WIN Foundation and Alfasigma together to fight one of the leading causes of preventable death: venous thrombosis. Italy as the hub of an international public awareness project on venous and lympha...
Read more
VEIN WEEK - Alfasigma leader among Vascular partners worldwide
This year, Alfasigma will be Sponsor of the Vein Week, organized by v-WIN Foundation (Scientific Society in Phlebology). The initiative will take place from April, 5th to 11th and on the occasion, a G...
Read more
Alfasigma acquires Lumeblue™ (Methylene Blue MMX) rights for EU distribution, consolidating its Gastro-Intestinal portfolio
Cosmo Pharmaceuticals will receive a €4m upfront payment Alfasigma plus double digit royalties. Lumeblue™ was ecently approved by EMA for the detection of lesions during colonoscopy. Alfasigma w...
Read more
The IDEA Journal is ready to start!
The International Digestive Experts Articles (IDEA) Journal is a quarterly scientific online journal focused on What’s new and What’s innovative in Gastroenterology worldwide, with the aim of diss...
Read more